Breakdown | ||||
Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|
Income Statement | Total Revenue | |||
0.00 | 0.00 | 0.00 | 0.00 | 120.00K | Gross Profit |
-37.00K | -120.00K | -106.00K | -86.00K | 120.00K | EBIT |
-17.93M | -34.46M | -26.56M | -9.23M | -17.61M | EBITDA |
-12.08M | -17.24M | -25.91M | -6.01M | -15.58M | Net Income Common Stockholders |
-11.90M | -16.06M | -26.65M | -5.07M | -14.40M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
166.00K | 2.03M | 19.55M | 298.00K | 1.52M | Total Assets |
11.86M | 14.54M | 49.63M | 33.40M | 31.61M | Total Debt |
1.30M | 3.73M | 1.09M | 1.79M | 963.00K | Net Debt |
1.13M | 1.71M | -18.47M | 1.49M | -561.00K | Total Liabilities |
14.61M | 12.65M | 30.85M | 6.55M | 10.70M | Stockholders Equity |
-2.75M | 1.89M | 18.78M | 26.85M | 18.09M |
Cash Flow | Free Cash Flow | |||
-12.74M | -16.84M | -15.05M | -7.25M | -10.12M | Operating Cash Flow |
-12.74M | -16.82M | -15.05M | -7.25M | -10.11M | Investing Cash Flow |
0.00 | 791.00K | 1.00M | -3.00K | 229.00K | Financing Cash Flow |
10.99M | -1.31M | 33.82M | 6.03M | 11.20M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
52 Neutral | $5.28B | 3.75 | -42.72% | 2.86% | 17.70% | 2.03% | |
51 Neutral | $20.34M | ― | -31.35% | ― | 603.12% | 68.27% | |
48 Neutral | $19.05M | 698.04 | 0.04% | ― | 10081.34% | ― | |
37 Underperform | $16.21M | ― | 354.78% | ― | ― | 64.19% | |
35 Underperform | $16.71M | ― | -150.67% | ― | ― | -126.54% | |
32 Underperform | $22.33M | ― | -154.54% | ― | ― | 66.72% | |
28 Underperform | $19.91M | ― | -541.17% | ― | ― | 99.43% |
On April 16, 2025, Allarity Therapeutics, Inc. restructured its Board of Directors to achieve a more balanced membership among its classes by moving Thomas H. Jensen from Class I to Class III. This change was made to ensure continuity in board service, with Mr. Jensen’s term now expiring in 2028. Additionally, the company announced that its 2025 annual meeting of stockholders will be held on June 13, 2025, with a record date set for April 16, 2025. The meeting date was advanced by more than 30 days from the previous year’s anniversary, prompting the company to file a Current Report to inform stockholders and outline the submission deadlines for stockholder proposals and nominations.
Spark’s Take on ALLR Stock
According to Spark, TipRanks’ AI Analyst, ALLR is a Underperform.
Allarity Therapeutics faces substantial financial challenges, with no revenue and consistent operational losses, which weigh heavily on its stock score. Technical indicators provide a neutral outlook without strong trends, and valuation is difficult due to negative earnings. These factors combine to result in a low score, highlighting significant risks for investors.
To see Spark’s full report on ALLR stock, click here.